Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

abstract：:Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...

journal_title：Neuro-oncology

authors： Hottinger AF,Pacheco P,Stupp R

更新日期：2016-10-01 00:00:00

abstract：:In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and...

journal_title：Neuro-oncology

authors： Hess KR,Wong ET,Jaeckle KA,Kyritsis AP,Levin VA,Prados MD,Yung WK

更新日期：1999-10-01 00:00:00

abstract：:We conducted a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in children and anaplastic ependymoma in patients of all ages. Between 1984 and 199...

journal_title：Neuro-oncology

authors： Levin VA,Lamborn K,Wara W,Davis R,Edwards M,Rabbitt J,Malec M,Prados MD

更新日期：2000-01-01 00:00:00

abstract：BACKGROUND:Diffuse midline glioma (DMG), H3 K27M-mutant occurs in both adult and pediatric populations. The characteristics of the two DMG groups were systematically explored in this study. METHODS: One-hundred-sixteen patients diagnosed with H3 K27M-mutant DMG in Beijing Tiantan Hospital from May 2016 to December 201...

journal_title：Neuro-oncology

authors： Jiang H,Yang K,Ren X,Cui Y,Li M,Lei Y,Lin S

更新日期：2019-08-24 00:00:00

abstract：:Grade II gliomas are morphologically and clinically heterogeneous tumors for which histopathological typing remains the major tool for clinical classification. To what extent the major histological subtypes - astrocytomas, oligodendrogliomas, and oligoastrocytomas - constitute true biological entities is largely unres...

journal_title：Neuro-oncology

authors： Hägerstrand D,Smits A,Eriksson A,Sigurdardottir S,Olofsson T,Hartman M,Nistér M,Kalimo H,Ostman A

更新日期：2008-02-01 00:00:00

abstract：:Protein kinase C alpha (PKC-alpha) is a cytoplasmic serine threonine kinase involved in regulating cell differentiation and proliferation. Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice. In this ...

journal_title：Neuro-oncology

authors： Grossman SA,Alavi JB,Supko JG,Carson KA,Priet R,Dorr FA,Grundy JS,Holmlund JT

更新日期：2005-01-01 00:00:00

abstract：:Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by ex...

journal_title：Neuro-oncology

authors： Abrey LE,Louis DN,Paleologos N,Lassman AB,Raizer JJ,Mason W,Finlay J,MacDonald DR,DeAngelis LM,Cairncross JG,Oligodendroglioma Study Group.

更新日期：2007-07-01 00:00:00

abstract：:Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates remain poor despite decades of clinical trials of conventional and novel, biologically targeted therapeutics. There is considerable evidence that most of these therapeutics do not reach their targets in the brain when administered...

journal_title：Neuro-oncology

authors： Vogelbaum MA,Aghi MK

更新日期：2015-03-01 00:00:00

abstract：:PDGFRA is a critical gene in glioma biology. Similar to EGFR, PDGFRA has been shown to be overexpressed, amplified, mutated, or truncated in gliomas, particularly glioblastomas. In addition, PDGFRA has been recently shown to be rearranged in glioblastoma. However, the frequency, cooccurrence, and clinical value of PDG...

journal_title：Neuro-oncology

authors： Alentorn A,Marie Y,Carpentier C,Boisselier B,Giry M,Labussière M,Mokhtari K,Hoang-Xuan K,Sanson M,Delattre JY,Idbaih A

更新日期：2012-11-01 00:00:00

abstract：Background:Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods:Using da...

journal_title：Neuro-oncology

authors： Leece R,Xu J,Ostrom QT,Chen Y,Kruchko C,Barnholtz-Sloan JS

更新日期：2017-10-19 00:00:00

abstract：BACKGROUND:No reliable estimates are available on the incidence of brain metastasis (BM) in cancer patients. This information is valuable for planning patient care and developing measures that may prevent or decrease the likelihood of metastatic brain disease. METHODS:We report the first population-based analysis on B...

journal_title：Neuro-oncology

authors： Villano JL,Durbin EB,Normandeau C,Thakkar JP,Moirangthem V,Davis FG

更新日期：2015-01-01 00:00:00

abstract：:Transforming growth factor-beta (TGF-beta) is a proinvasive and immunosuppressive cytokine that plays a major role in the malignant phenotype of gliomas. One novel strategy of disabling TGF-beta activity in gliomas is to disrupt the signaling cascade at the level of the TGF-beta receptor I (TGF-betaRI) kinase, thus ab...

journal_title：Neuro-oncology

authors： Tran TT,Uhl M,Ma JY,Janssen L,Sriram V,Aulwurm S,Kerr I,Lam A,Webb HK,Kapoun AM,Kizer DE,McEnroe G,Hart B,Axon J,Murphy A,Chakravarty S,Dugar S,Protter AA,Higgins LS,Wick W,Weller M,Wong DH

更新日期：2007-07-01 00:00:00

abstract：BACKGROUND:Temporal muscle thickness (TMT) was described as a surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma. METHODS:TMT was analyzed on cranial MR images of 596 patients with progression of glioblastoma after radiochemo...

journal_title：Neuro-oncology

authors： Furtner J,Genbrugge E,Gorlia T,Bendszus M,Nowosielski M,Golfinopoulos V,Weller M,van den Bent MJ,Wick W,Preusser M

更新日期：2019-12-17 00:00:00

abstract：:A 67-year-old man presented with a 7-month history of insidiously progressive chorea, ataxia, and vertigo. Neurologic examination revealed deficits referable to the basal nuclei, cerebellar vermis, and vestibular nuclei. Small-cell lung cancer was diagnosed by fine-needle biopsy of a parahilar mass. After chemotherapy...

journal_title：Neuro-oncology

authors： Tremont-Lukats IW,Fuller GN,Ribalta T,Giglio P,Groves MD

更新日期：2002-07-01 00:00:00

abstract：Background:Copy number alterations form prognostic molecular subtypes of glioblastoma with clear differences in median overall survival. In this study, we leverage molecular data from several glioblastoma cohorts to define the distribution of copy number subtypes across random cohorts as well as cohorts with selection ...

journal_title：Neuro-oncology

authors： Cimino PJ,McFerrin L,Wirsching HG,Arora S,Bolouri H,Rabadan R,Weller M,Holland EC

更新日期：2018-09-03 00:00:00

abstract：:The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast mate...

journal_title：Neuro-oncology

authors： Sarkaria JN,Hu LS,Parney IF,Pafundi DH,Brinkmann DH,Laack NN,Giannini C,Burns TC,Kizilbash SH,Laramy JK,Swanson KR,Kaufmann TJ,Brown PD,Agar NYR,Galanis E,Buckner JC,Elmquist WF

更新日期：2018-01-22 00:00:00

abstract：:Although treatment of medulloblastoma has improved, at least 30% of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. Th...

journal_title：Neuro-oncology

authors： Studebaker AW,Kreofsky CR,Pierson CR,Russell SJ,Galanis E,Raffel C

更新日期：2010-10-01 00:00:00

abstract：:We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogen...

journal_title：Neuro-oncology

authors： Perrone F,Da Riva L,Orsenigo M,Losa M,Jocollè G,Millefanti C,Pastore E,Gronchi A,Pierotti MA,Pilotti S

更新日期：2009-12-01 00:00:00

abstract：:Diffuse low-grade glioma grows, migrates along white matter tracts, and progresses to high-grade glioma. Rather than a "wait and see" policy, an aggressive attitude is now recommended, with early surgery as the first therapy. Intraoperative mapping, with maximal resection according to functional boundaries, is associa...

journal_title：Neuro-oncology

authors： Duffau H,Taillandier L

更新日期：2015-03-01 00:00:00

abstract：Background:Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens. Methods:We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable inhibitor of type III...

journal_title：Neuro-oncology

authors： Batchelor TT,Gerstner ER,Ye X,Desideri S,Duda DG,Peereboom D,Lesser GJ,Chowdhary S,Wen PY,Grossman S,Supko JG

更新日期：2017-04-01 00:00:00

abstract：:Background Nuclear factor IA (NFIA), a transcription factor and essential regulator in embryonic glial development, is highly expressed in human glioblastoma (GBM) compared with normal brain, but its contribution to GBM and cancer pathogenesis is unknown. Here we demonstrate a novel role for NFIA in promoting growth a...

journal_title：Neuro-oncology

authors： Lee JS,Xiao J,Patel P,Schade J,Wang J,Deneen B,Erdreich-Epstein A,Song HR

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:The influence of survivin isoforms on outcome in glioblastoma is poorly understood. We analyzed the dominant anti-apoptotic transcript variants of survivin using expression data and modeled them in vivo to determine their impact on glioma formation and progression. METHODS:Using data from low- and high-grad...

journal_title：Neuro-oncology

authors： Doucette T,Latha K,Yang Y,Fuller GN,Rao A,Rao G

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:This study aimed to evaluate the prognostic significance of co-polsomy of chromosome 1q and 19p in 1p/19q codeleted oligodendroglial tumors (ODGs). METHODS:In a series of 148 ODGs with 1p/19q deletion, co-polysomy of 1q and 19p was detected by fluorescence in situ hybridization (FISH). Log-rank analysis and...

journal_title：Neuro-oncology

authors： Ren X,Jiang H,Cui X,Cui Y,Ma J,Jiang Z,Sui D,Lin S

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Breast cancer (BC) is the second most common cause of brain metastases (BM). Optimal management of BM from BC is still debated. In an attempt to provide appropriate treatment and to assist with optimal patient selection, several specific prognostic classifications for BM from BC have been established. We eva...

journal_title：Neuro-oncology

authors： Tabouret E,Metellus P,Gonçalves A,Esterni B,Charaffe-Jauffret E,Viens P,Tallet A

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Outcomes for patients with recurrent glioblastoma multiforme (GBM) are poor and may be improved by immunotherapy. We investigated the safety and efficacy of an autologous heat-shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent GBM. METHODS:In this open-label, single-arm, phase I...

journal_title：Neuro-oncology

authors： Bloch O,Crane CA,Fuks Y,Kaur R,Aghi MK,Berger MS,Butowski NA,Chang SM,Clarke JL,McDermott MW,Prados MD,Sloan AE,Bruce JN,Parsa AT

更新日期：2014-01-01 00:00:00

abstract：:In order to compare in vivo metabolism between malignant gliomas and normal brain, (13)C magnetic resonance (MR) spectroscopic imaging data were acquired from rats with human glioblastoma xenografts (U-251 MG and U-87 MG) and normal rats, following injection of hyperpolarized [1-(13)C]-pyruvate. The median signal-to-n...

journal_title：Neuro-oncology

authors： Park I,Larson PE,Zierhut ML,Hu S,Bok R,Ozawa T,Kurhanewicz J,Vigneron DB,Vandenberg SR,James CD,Nelson SJ

更新日期：2010-02-01 00:00:00

abstract：:This study was conducted to determine the maximum tolerated dose and dose-limiting toxicity of irinotecan (CPT-11) administered every 3 weeks to adults with progressive malignant glioma who were treated with enzyme inducing antiepileptic drug (EIAED) therapy, and to compare the pharmacokinetics with those in patients ...

journal_title：Neuro-oncology

authors： Prados MD,Yung WK,Jaeckle KA,Robins HI,Mehta MP,Fine HA,Wen PY,Cloughesy TF,Chang SM,Nicholas MK,Schiff D,Greenberg HS,Junck L,Fink KL,Hess KR,Kuhn J,North American Brain Tumor Consortium study.

更新日期：2004-01-01 00:00:00

abstract：:Intradural spinal tumors are rare tumors of the central nervous system. Due to the eloquence of the spinal cord and its tracts, the compact architecture of the cord and nerves, and the infiltrative nature of some of these tumors, surgical resection is difficult to achieve without causing neurological deficits. Likewis...

journal_title：Neuro-oncology

authors： Abd-El-Barr MM,Huang KT,Moses ZB,Iorgulescu JB,Chi JH

更新日期：2018-05-18 00:00:00

abstract：BACKGROUND:Primary central nervous system lymphomas, predominantly diffuse large B-cell lymphomas (PCNS-DLBCL), are aggressive malignancies, and no histopathological variables with independent prognostic value are currently available. The aim of this study is to determine the prognostic value of histopathological varia...

journal_title：Neuro-oncology

authors： He M,Zuo C,Wang J,Liu J,Jiao B,Zheng J,Cai Z

更新日期：2013-06-01 00:00:00

abstract：:Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem. Contrary to hematologic adverse effects, which can be treated with hematopoetic growth factors, neither prophylaxis nor specific treatment is available, and only symptomatic treatment can be offered. Neurotoxic drugs are becom...

journal_title：Neuro-oncology

authors： Grisold W,Cavaletti G,Windebank AJ

更新日期：2012-09-01 00:00:00